Because DNA from Japanese patients with fingolimod-PML was not available for HLA genotyping, we studied the relationship between anti-JCV antibody serostatus and HLA class II alleles in Japanese MS patients with and without fingolimod to assess whether MS-susceptible HLA class II alleles influenced anti-JCV antibody serostatus. The gene discussed is PML; the disease is myeloid sarcoma.